reveromycin a

Reveromycin A is the major component of a complex of spiroketal antibiotics isolated from Streptomyces sp. It inhibits the mitogenic activity of epidermal growth factor in Balb/MK cells (IC50 = 0.7 μg/ml), displays antiproliferative activity against human KB and K562 tumor cell lines (IC50s = 1.9 and 1.6 μg/ml, respectively), and demonstrates antifungal activity against C. albicans (MIC = 2 μg/ml at pH 3). Reveromycin A also has been shown to inhibit bone resorption by inducing apoptosis in osteoclasts with an IC50 value of 0.7 μM.

Reveromycin C是一种聚酮化合物，最初从链霉菌中提取，具有抗白色念珠菌的抗真菌活性，在pH 3和pH 7.4时的MIC分别为2.0和>500 μg/mL。Reveromycin C可抑制Balb/MK小鼠表皮细胞系中EGF诱导的有丝分裂原活性。它还能逆转肉瘤病毒转化的NRK大鼠肾细胞的形态（EC50=1.58 μg/mL），并抑制KB细胞和K562人慢性粒细胞白血病细胞的增殖，两者的IC50均为2.0 μg/mL。

Reveromycin D is a bacterial metabolite originally isolated from Streptomyces. It inhibits EGF-induced mitogenic activity in Balb/MK cells and has pH-dependent antifungal activity against C. albicans (MICs = 2 and >500 μg/ml at pH 3 and 7.4, respectively). Reveromycin D also inhibits proliferation of KB and K562 cells (IC50s = 1.6 and 1.3 μg/ml, respectively).

Reveromycin B is a spiroketal bacterial metabolite originally isolated from Streptomyces. It inhibits EGF-induced mitogenic activity in Balb/MK cells (IC50 = 6 μg/ml) and exhibits pH-dependent antifungal activity against C. albicans (MICs = 15.6 and >500 μg/ml at pH 3.0 and 7.4, respectively). Unlike reveromycin A and reveromycin C , reveromycin B does not inhibit proliferation of KB and K562 cells.